Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | MGMT | P16455 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11468514 | 1.00 | PDPK1 (0.36) | PDPK1GDAKDRAURKBMGMT | |
| SCHEMBL11478249 | 1.00 | PDPK1 (0.36) | PDPK1GDAKDRAURKBMGMT | |
| Phosphoric Acid SCHEMBL1130273 | 0.77 | PDPK1 (0.39) | PDPK1GDAKDRAURKB | |
| SCHEMBL11875859 | 0.75 | — | — | |
| SCHEMBL8102858 | 0.73 | ADORA1 (0.43) | PDPK1GDAKDRAURKB | |
| SCHEMBL9393271 | 0.72 | PDPK1 (0.43) | PDPK1GDAKDRAURKB | |
| SCHEMBL240029 | 0.72 | PDPK1 (0.43) | PDPK1GDAKDRAURKB | |
| SCHEMBL4436406 | 0.72 | PDPK1 (0.43) | PDPK1GDAKDRAURKB | |
| SCHEMBL2636634 | 0.72 | PDPK1 (0.43) | PDPK1GDAKDRAURKB | |
| SCHEMBL2010793 | 0.72 | PDPK1 (0.43) | PDPK1GDAKDRAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0852499-B1 | THERAPEUTIC AZIDE COMPOUNDS | UNIV GEORGIA RES FOUND (US) | 2010-03-03 | — | — | EP | disclosed |
| US-6949521-B2 | Therapeutic azide compounds | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20010036930-A1 | Therapeutic azide compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2001-11-01 | — | — | US | disclosed |
| US-6271212-B1 | MIXTURE WITH CARRIER | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. | 2001-08-07 | — | — | US | disclosed |
| EP-0624098-B1 | PROCESS OF CONJUGATION OF ANTIVIRAL NUCLEOSIDES WITH LACTOSAMINATED HUMAN ALBUMIN | BALDACCI LAB SPA (IT) | 2000-03-15 | — | — | EP | disclosed |
| EP-0852499-A1 | THERAPEUTIC AZIDE COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1998-07-15 | — | — | EP | disclosed |
| WO-1997009052-A1 | THERAPEUTIC AZIDE COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
| US-5594110-A | REACTION OF NUCLEOSIDE IN THE FORM OF AN IMIDAZOLIDE AT A PH ABOVE 7.5 | LABORATORI BALDACCI SPA (IT) | 1997-01-14 | — | — | US | disclosed |
| EP-0624098-A1 | PROCESS OF CONJUGATION OF ANTIVIRAL NUCLEOSIDES WITH LACTOSAMINATED HUMAN ALBUMIN | LABORATORI BALDACCI Spa (IT) | 1994-11-17 | — | — | EP | disclosed |
| WO-1994012218-A1 | PROCESS OF CONJUGATION OF ANTIVIRAL NUCLEOSIDES WITH LACTOSAMINATED HUMAN ALBUMIN | LABORATORI BALDACCI S.P.A. (IT) | 1994-06-09 | — | — | WO | disclosed |
| EP-0103783-A2 | Dermatological preparation | Dr. Thilo & Co. GmbH (DE) | 1984-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036930-A1 | Therapeutic azide compounds | ADA, ADK, DCK | PDPK1 409/4885GDA 186/4885KDR 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.